ID GBA1_MOUSE Reviewed; 515 AA. AC P17439; Q78NR7; DT 01-AUG-1990, integrated into UniProtKB/Swiss-Prot. DT 01-AUG-1990, sequence version 1. DT 27-MAR-2024, entry version 186. DE RecName: Full=Lysosomal acid glucosylceramidase {ECO:0000305}; DE Short=Lysosomal acid GCase {ECO:0000303|PubMed:24211208}; DE EC=3.2.1.45 {ECO:0000269|PubMed:1594045, ECO:0000269|PubMed:24211208}; DE AltName: Full=Acid beta-glucosidase; DE AltName: Full=Beta-glucocerebrosidase; DE AltName: Full=Cholesterol glucosyltransferase {ECO:0000305|PubMed:24211208}; DE Short=SGTase {ECO:0000303|PubMed:24211208}; DE EC=2.4.1.- {ECO:0000269|PubMed:24211208}; DE AltName: Full=Cholesteryl-beta-glucosidase {ECO:0000250|UniProtKB:P04062}; DE EC=3.2.1.- {ECO:0000250|UniProtKB:P04062}; DE AltName: Full=D-glucosyl-N-acylsphingosine glucohydrolase; DE AltName: Full=Lysosomal cholesterol glycosyltransferase {ECO:0000305}; DE AltName: Full=Lysosomal galactosylceramidase {ECO:0000305}; DE EC=3.2.1.46 {ECO:0000250|UniProtKB:P04062}; DE AltName: Full=Lysosomal glycosylceramidase {ECO:0000305}; DE Flags: Precursor; GN Name=Gba1; Synonyms=Gba {ECO:0000312|MGI:MGI:95665}; OS Mus musculus (Mouse). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; OC Murinae; Mus; Mus. OX NCBI_TaxID=10090; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=2740343; DOI=10.1073/pnas.86.13.5049; RA O'Neill R.R., Tokoru T., Kozak C.A., Brady R.O.; RT "Comparison of the chromosomal localization of murine and human RT glucocerebrosidase genes and of the deduced amino acid sequences."; RL Proc. Natl. Acad. Sci. U.S.A. 86:5049-5053(1989). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RC STRAIN=129/SvJ; RA Sinclair G., Wilson M.D., McKinnel L., Koop B.F., Choy F.Y.M.; RT "Comparative sequence analysis of the mouse and human GBA locus."; RL Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC STRAIN=C57BL/6J; RX PubMed=16141072; DOI=10.1126/science.1112014; RA Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N., RA Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K., RA Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J., RA Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R., RA Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T., RA Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A., RA Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., RA Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M., RA Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S., RA Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E., RA Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D., RA Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M., RA Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H., RA Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V., RA Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S., RA Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H., RA Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N., RA Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F., RA Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., RA Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., RA Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C., RA Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y., RA Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S., RA Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K., RA Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R., RA van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H., RA Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M., RA Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C., RA Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S., RA Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K., RA Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M., RA Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C., RA Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A., RA Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.; RT "The transcriptional landscape of the mammalian genome."; RL Science 309:1559-1563(2005). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC STRAIN=FVB/N; TISSUE=Mammary gland; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-18. RC STRAIN=BALB/cJ; RX PubMed=1317175; DOI=10.1016/s0006-291x(05)80049-x; RA Carstea E.D., Murray G.J., O'Neill R.R.; RT "Molecular and functional characterization of the murine glucocerebrosidase RT gene."; RL Biochem. Biophys. Res. Commun. 184:1477-1483(1992). RN [6] RP PROTEIN SEQUENCE OF 210-217, AND IDENTIFICATION BY MASS SPECTROMETRY. RC STRAIN=OF1; TISSUE=Hippocampus; RA Lubec G., Sunyer B., Chen W.-Q.; RL Submitted (JAN-2009) to UniProtKB. RN [7] RP CATALYTIC ACTIVITY, AND DISRUPTION PHENOTYPE. RX PubMed=1594045; DOI=10.1038/357407a0; RA Tybulewicz V.L., Tremblay M.L., LaMarca M.E., Willemsen R., RA Stubblefield B.K., Winfield S., Zablocka B., Sidransky E., Martin B.M., RA Huang S.P.; RT "Animal model of Gaucher's disease from targeted disruption of the mouse RT glucocerebrosidase gene."; RL Nature 357:407-410(1992). RN [8] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-165. RC TISSUE=Epidermis; RX PubMed=16170054; DOI=10.1074/mcp.m500203-mcp200; RA Uematsu R., Furukawa J., Nakagawa H., Shinohara Y., Deguchi K., Monde K., RA Nishimura S.; RT "High throughput quantitative glycomics and glycoform-focused proteomics of RT murine dermis and epidermis."; RL Mol. Cell. Proteomics 4:1977-1989(2005). RN [9] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-289. RX PubMed=19349973; DOI=10.1038/nbt.1532; RA Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M., RA Schiess R., Aebersold R., Watts J.D.; RT "Mass-spectrometric identification and relative quantification of N-linked RT cell surface glycoproteins."; RL Nat. Biotechnol. 27:378-386(2009). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Brain, Kidney, Liver, Lung, Pancreas, Spleen, and Testis; RX PubMed=21183079; DOI=10.1016/j.cell.2010.12.001; RA Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R., RA Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.; RT "A tissue-specific atlas of mouse protein phosphorylation and expression."; RL Cell 143:1174-1189(2010). RN [11] RP DISRUPTION PHENOTYPE. RX PubMed=22665763; DOI=10.1073/pnas.1200941109; RA Liu J., Halene S., Yang M., Iqbal J., Yang R., Mehal W.Z., Chuang W.L., RA Jain D., Yuen T., Sun L., Zaidi M., Mistry P.K.; RT "Gaucher disease gene GBA functions in immune regulation."; RL Proc. Natl. Acad. Sci. U.S.A. 109:10018-10023(2012). RN [12] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND ACTIVITY REGULATION. RX PubMed=24211208; DOI=10.1016/j.bbrc.2013.10.145; RA Akiyama H., Kobayashi S., Hirabayashi Y., Murakami-Murofushi K.; RT "Cholesterol glucosylation is catalyzed by transglucosylation reaction of RT beta-glucosidase 1."; RL Biochem. Biophys. Res. Commun. 441:838-843(2013). RN [13] RP INTERACTION WITH GRN. RX PubMed=27789271; DOI=10.1016/j.ebiom.2016.10.010; RA Jian J., Tian Q.Y., Hettinghouse A., Zhao S., Liu H., Wei J., Grunig G., RA Zhang W., Setchell K.D.R., Sun Y., Overkleeft H.S., Chan G.L., Liu C.J.; RT "Progranulin Recruits HSP70 to beta-Glucocerebrosidase and Is Therapeutic RT Against Gaucher Disease."; RL EBioMedicine 13:212-224(2016). RN [14] RP FUNCTION. RX PubMed=27378698; DOI=10.1093/hmg/ddw185; RA Magalhaes J., Gegg M.E., Migdalska-Richards A., Doherty M.K., RA Whitfield P.D., Schapira A.H.; RT "Autophagic lysosome reformation dysfunction in glucocerebrosidase RT deficient cells: relevance to Parkinson disease."; RL Hum. Mol. Genet. 25:3432-3445(2016). CC -!- FUNCTION: Glucosylceramidase that catalyzes, within the lysosomal CC compartment, the hydrolysis of glucosylceramides/GlcCers (such as beta- CC D-glucosyl-(1<->1')-N-acylsphing-4-enine) into free ceramides (such as CC N-acylsphing-4-enine) and glucose (PubMed:24211208). Plays a central CC role in the degradation of complex lipids and the turnover of cellular CC membranes (PubMed:27378698). Through the production of ceramides, CC participates in the PKC-activated salvage pathway of ceramide formation CC (By similarity). Catalyzes the glucosylation of cholesterol, through a CC transglucosylation reaction where glucose is transferred from GlcCer to CC cholesterol (PubMed:24211208). GlcCer containing mono-unsaturated fatty CC acids (such as beta-D-glucosyl-N-(9Z-octadecenoyl)-sphing-4-enine) are CC preferred as glucose donors for cholesterol glucosylation when compared CC with GlcCer containing same chain length of saturated fatty acids (such CC as beta-D-glucosyl-N-octadecanoyl-sphing-4-enine) (By similarity). CC Under specific conditions, may alternatively catalyze the reverse CC reaction, transferring glucose from cholesteryl 3-beta-D-glucoside to CC ceramide (By similarity). Can also hydrolyze cholesteryl 3-beta-D- CC glucoside producing glucose and cholesterol (By similarity). Catalyzes CC the hydrolysis of galactosylceramides/GalCers (such as beta-D- CC galactosyl-(1<->1')-N-acylsphing-4-enine), as well as the transfer of CC galactose between GalCers and cholesterol in vitro, but with lower CC activity than with GlcCers (By similarity). Contrary to GlcCer and CC GalCer, xylosylceramide/XylCer (such as beta-D-xyosyl-(1<->1')-N- CC acylsphing-4-enine) is not a good substrate for hydrolysis, however it CC is a good xylose donor for transxylosylation activity to form CC cholesteryl 3-beta-D-xyloside (By similarity). CC {ECO:0000250|UniProtKB:P04062, ECO:0000269|PubMed:24211208, CC ECO:0000269|PubMed:27378698}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine + H2O = an N- CC acylsphing-4-enine + D-glucose; Xref=Rhea:RHEA:13269, CC ChEBI:CHEBI:4167, ChEBI:CHEBI:15377, ChEBI:CHEBI:22801, CC ChEBI:CHEBI:52639; EC=3.2.1.45; CC Evidence={ECO:0000269|PubMed:24211208}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:13270; CC Evidence={ECO:0000305|PubMed:24211208}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a beta-D-galactosyl-(1<->1')-N-acylsphing-4-enine + H2O = an CC N-acylsphing-4-enine + D-galactose; Xref=Rhea:RHEA:14297, CC ChEBI:CHEBI:4139, ChEBI:CHEBI:15377, ChEBI:CHEBI:18390, CC ChEBI:CHEBI:52639; EC=3.2.1.46; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:14298; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC -!- CATALYTIC ACTIVITY: CC Reaction=cholesteryl 3-beta-D-glucoside + H2O = cholesterol + D- CC glucose; Xref=Rhea:RHEA:11956, ChEBI:CHEBI:4167, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:16113, ChEBI:CHEBI:17495; CC Evidence={ECO:0000269|PubMed:24211208}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:11957; CC Evidence={ECO:0000305|PubMed:24211208}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine + cholesterol CC = an N-acylsphing-4-enine + cholesteryl 3-beta-D-glucoside; CC Xref=Rhea:RHEA:58264, ChEBI:CHEBI:16113, ChEBI:CHEBI:17495, CC ChEBI:CHEBI:22801, ChEBI:CHEBI:52639; CC Evidence={ECO:0000269|PubMed:24211208}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:58265; CC Evidence={ECO:0000305|PubMed:24211208}; CC PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:58266; CC Evidence={ECO:0000305}; CC -!- CATALYTIC ACTIVITY: CC Reaction=beta-D-glucosyl-(1<->1')-N-hexadecanoylsphing-4-enine + CC cholesterol = cholesteryl 3-beta-D-glucoside + N-hexadecanoylsphing- CC 4-enine; Xref=Rhea:RHEA:58316, ChEBI:CHEBI:16113, ChEBI:CHEBI:17495, CC ChEBI:CHEBI:72959, ChEBI:CHEBI:84716; CC Evidence={ECO:0000269|PubMed:24211208}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:58317; CC Evidence={ECO:0000305|PubMed:24211208}; CC PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:58318; CC Evidence={ECO:0000305}; CC -!- CATALYTIC ACTIVITY: CC Reaction=beta-D-glucosyl-N-(9Z-octadecenoyl)-sphing-4E-enine + CC cholesterol = cholesteryl 3-beta-D-glucoside + N-(9Z-octadecenoyl)- CC sphing-4-enine; Xref=Rhea:RHEA:58324, ChEBI:CHEBI:16113, CC ChEBI:CHEBI:17495, ChEBI:CHEBI:77996, ChEBI:CHEBI:139140; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:58325; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:58326; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC -!- CATALYTIC ACTIVITY: CC Reaction=beta-D-glucosyl-N-octanoylsphing-4E-enine + cholesterol = CC cholesteryl 3-beta-D-glucoside + N-octanoylsphing-4-enine; CC Xref=Rhea:RHEA:70303, ChEBI:CHEBI:16113, ChEBI:CHEBI:17495, CC ChEBI:CHEBI:45815, ChEBI:CHEBI:65222; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:70304; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:70305; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC -!- CATALYTIC ACTIVITY: CC Reaction=beta-D-glucosyl-N-dodecanoylsphing-4-enine + cholesterol = CC cholesteryl 3-beta-D-glucoside + N-dodecanoylsphing-4-enine; CC Xref=Rhea:RHEA:70307, ChEBI:CHEBI:16113, ChEBI:CHEBI:17495, CC ChEBI:CHEBI:72956, ChEBI:CHEBI:76297; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:70308; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:70309; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC -!- CATALYTIC ACTIVITY: CC Reaction=beta-D-glucosyl-(1<->1)-N-octadecanoylsphing-4-enine + CC cholesterol = cholesteryl 3-beta-D-glucoside + N-octadecanoylsphing- CC 4-enine; Xref=Rhea:RHEA:70311, ChEBI:CHEBI:16113, ChEBI:CHEBI:17495, CC ChEBI:CHEBI:72961, ChEBI:CHEBI:84719; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:70312; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:70313; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC -!- CATALYTIC ACTIVITY: CC Reaction=beta-D-glucosyl-(1<->1')-N-(15Z-tetracosenoyl)-sphing-4-enine CC + cholesterol = cholesteryl 3-beta-D-glucoside + N-(15Z- CC tetracosenoyl)-sphing-4-enine; Xref=Rhea:RHEA:70315, CC ChEBI:CHEBI:16113, ChEBI:CHEBI:17495, ChEBI:CHEBI:74450, CC ChEBI:CHEBI:76302; Evidence={ECO:0000250|UniProtKB:P04062}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:70316; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:70317; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a beta-D-galactosyl-(1<->1')-N-acylsphing-4-enine + CC cholesterol = an N-acylsphing-4-enine + cholesteryl 3-beta-D- CC galactoside; Xref=Rhea:RHEA:70235, ChEBI:CHEBI:16113, CC ChEBI:CHEBI:18390, ChEBI:CHEBI:52639, ChEBI:CHEBI:189066; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:70236; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:70237; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1-(beta-D-galactosyl)-N-dodecanoylsphing-4-enine + cholesterol CC = cholesteryl 3-beta-D-galactoside + N-dodecanoylsphing-4-enine; CC Xref=Rhea:RHEA:70255, ChEBI:CHEBI:16113, ChEBI:CHEBI:72956, CC ChEBI:CHEBI:73432, ChEBI:CHEBI:189066; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:70256; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:70257; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a beta-D-xylosyl-(1<->1')-N-acylsphing-4-enine + cholesterol = CC an N-acylsphing-4-enine + cholesteryl 3-beta-D-xyloside; CC Xref=Rhea:RHEA:70239, ChEBI:CHEBI:16113, ChEBI:CHEBI:52639, CC ChEBI:CHEBI:189067, ChEBI:CHEBI:189068; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:70240; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC -!- CATALYTIC ACTIVITY: CC Reaction=beta-D-xylosyl-(1<->1')-N-(9Z-octadecenoyl)-sphing-4-enine + CC cholesterol = cholesteryl 3-beta-D-xyloside + N-(9Z-octadecenoyl)- CC sphing-4-enine; Xref=Rhea:RHEA:70251, ChEBI:CHEBI:16113, CC ChEBI:CHEBI:77996, ChEBI:CHEBI:189067, ChEBI:CHEBI:189081; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:70252; CC Evidence={ECO:0000250|UniProtKB:P04062}; CC -!- ACTIVITY REGULATION: Inhibited by conduritol B epoxide/CBE. CC {ECO:0000269|PubMed:24211208}. CC -!- PATHWAY: Steroid metabolism; cholesterol metabolism. CC {ECO:0000269|PubMed:24211208}. CC -!- PATHWAY: Sphingolipid metabolism. {ECO:0000269|PubMed:24211208}. CC -!- SUBUNIT: Interacts with saposin-C. Interacts with SCARB2. Interacts CC with TCP1 (By similarity). Interacts with GRN; this interaction CC prevents aggregation of GBA1-SCARB2 complex via interaction with HSPA1A CC upon stress (PubMed:27789271). {ECO:0000250|UniProtKB:P04062, CC ECO:0000269|PubMed:27789271}. CC -!- SUBCELLULAR LOCATION: Lysosome membrane {ECO:0000250|UniProtKB:P04062}; CC Peripheral membrane protein {ECO:0000250|UniProtKB:P04062}; Lumenal CC side {ECO:0000250|UniProtKB:P04062}. Note=Interaction with saposin-C CC promotes membrane [?]association. Targeting to lysosomes occurs through CC an alternative MPR-independent mechanism via SCARB2. CC {ECO:0000250|UniProtKB:P04062}. CC -!- DISRUPTION PHENOTYPE: Homozygous knockout mice die within 24 hours of CC birth (PubMed:1594045). They are under weight, respire abnormally and CC show rapidly progressing cyanosis (PubMed:1594045). Feeding and CC movement are also decreased in these mice (PubMed:1594045). Macrophages CC accumulating glucosylceramides in tubular lysosomal deposits are found CC in liver (in Kupffer cells), bone marrow, spleen and brain CC (PubMed:1594045). Hematopoietic stem cells conditional knockout of CC GBA1, leads to widespread and organ-specific dysfunction of immune CC cells. Thymus shows the earliest alteration with features of impaired CC T-cell maturation, aberrant B-cell recruitment, enhanced antigen CC presentation, and impaired egress of mature thymocytes CC (PubMed:22665763). {ECO:0000269|PubMed:1594045, CC ECO:0000269|PubMed:22665763}. CC -!- SIMILARITY: Belongs to the glycosyl hydrolase 30 family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M24119; AAA37671.1; -; mRNA. DR EMBL; AY115108; AAM66757.1; -; Genomic_DNA. DR EMBL; AK082767; BAC38609.1; -; mRNA. DR EMBL; BC006663; AAH06663.1; -; mRNA. DR EMBL; M89949; AAA37665.1; -; Genomic_DNA. DR CCDS; CCDS17493.1; -. DR PIR; A32931; A32931. DR RefSeq; NP_001070879.1; NM_001077411.2. DR RefSeq; NP_032120.1; NM_008094.5. DR AlphaFoldDB; P17439; -. DR SMR; P17439; -. DR BioGRID; 199844; 11. DR IntAct; P17439; 3. DR STRING; 10090.ENSMUSP00000130660; -. DR BindingDB; P17439; -. DR ChEMBL; CHEMBL2278; -. DR SwissLipids; SLP:000001930; -. DR CAZy; GH30; Glycoside Hydrolase Family 30. DR GlyConnect; 2339; 3 N-Linked glycans (3 sites). DR GlyCosmos; P17439; 5 sites, 3 glycans. DR GlyGen; P17439; 5 sites, 3 N-linked glycans (3 sites). DR iPTMnet; P17439; -. DR PhosphoSitePlus; P17439; -. DR SwissPalm; P17439; -. DR EPD; P17439; -. DR jPOST; P17439; -. DR MaxQB; P17439; -. DR PaxDb; 10090-ENSMUSP00000130660; -. DR PeptideAtlas; P17439; -. DR ProteomicsDB; 268831; -. DR Pumba; P17439; -. DR Antibodypedia; 1678; 565 antibodies from 34 providers. DR DNASU; 14466; -. DR Ensembl; ENSMUST00000077367.11; ENSMUSP00000076589.5; ENSMUSG00000028048.12. DR Ensembl; ENSMUST00000167998.2; ENSMUSP00000130660.2; ENSMUSG00000028048.12. DR GeneID; 14466; -. DR KEGG; mmu:14466; -. DR UCSC; uc008pyb.2; mouse. DR AGR; MGI:95665; -. DR CTD; 2629; -. DR MGI; MGI:95665; Gba1. DR VEuPathDB; HostDB:ENSMUSG00000028048; -. DR eggNOG; KOG2566; Eukaryota. DR GeneTree; ENSGT00390000009464; -. DR HOGENOM; CLU_014379_1_2_1; -. DR InParanoid; P17439; -. DR OMA; FGGIAWH; -. DR OrthoDB; 3473901at2759; -. DR PhylomeDB; P17439; -. DR TreeFam; TF314254; -. DR BRENDA; 3.2.1.45; 3474. DR Reactome; R-MMU-9840310; Glycosphingolipid catabolism. DR UniPathway; UPA00296; -. DR BioGRID-ORCS; 14466; 6 hits in 80 CRISPR screens. DR ChiTaRS; Gba; mouse. DR PRO; PR:P17439; -. DR Proteomes; UP000000589; Chromosome 3. DR RNAct; P17439; Protein. DR Bgee; ENSMUSG00000028048; Expressed in esophagus and 289 other cell types or tissues. DR ExpressionAtlas; P17439; baseline and differential. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005615; C:extracellular space; IDA:MGI. DR GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB. DR GO; GO:0043202; C:lysosomal lumen; IDA:BHF-UCL. DR GO; GO:0005765; C:lysosomal membrane; IDA:BHF-UCL. DR GO; GO:0005764; C:lysosome; IDA:UniProtKB. DR GO; GO:0005802; C:trans-Golgi network; IDA:UniProtKB. DR GO; GO:0008422; F:beta-glucosidase activity; IDA:MGI. DR GO; GO:0004336; F:galactosylceramidase activity; IEA:RHEA. DR GO; GO:0004348; F:glucosylceramidase activity; IDA:UniProtKB. DR GO; GO:0046527; F:glucosyltransferase activity; IDA:UniProtKB. DR GO; GO:0016787; F:hydrolase activity; IDA:MGI. DR GO; GO:0005124; F:scavenger receptor binding; ISO:MGI. DR GO; GO:0005102; F:signaling receptor binding; IPI:BHF-UCL. DR GO; GO:0050295; F:steryl-beta-glucosidase activity; ISS:UniProtKB. DR GO; GO:0019882; P:antigen processing and presentation; IMP:MGI. DR GO; GO:1905037; P:autophagosome organization; IMP:ARUK-UCL. DR GO; GO:0006914; P:autophagy; IMP:UniProtKB. DR GO; GO:1901805; P:beta-glucoside catabolic process; ISO:MGI. DR GO; GO:0048854; P:brain morphogenesis; IMP:MGI. DR GO; GO:0048469; P:cell maturation; IMP:MGI. DR GO; GO:0009267; P:cellular response to starvation; IMP:ParkinsonsUK-UCL. DR GO; GO:0071356; P:cellular response to tumor necrosis factor; ISO:MGI. DR GO; GO:0007417; P:central nervous system development; IMP:MGI. DR GO; GO:0046513; P:ceramide biosynthetic process; ISO:MGI. DR GO; GO:0021694; P:cerebellar Purkinje cell layer formation; IMP:MGI. DR GO; GO:0008203; P:cholesterol metabolic process; IDA:UniProtKB. DR GO; GO:0008340; P:determination of adult lifespan; IMP:MGI. DR GO; GO:0061436; P:establishment of skin barrier; ISO:MGI. DR GO; GO:0006680; P:glucosylceramide catabolic process; IDA:UniProtKB. DR GO; GO:0006678; P:glucosylceramide metabolic process; IMP:MGI. DR GO; GO:0071425; P:hematopoietic stem cell proliferation; IMP:MGI. DR GO; GO:0048872; P:homeostasis of number of cells; IMP:MGI. DR GO; GO:0030259; P:lipid glycosylation; IDA:UniProtKB. DR GO; GO:0019915; P:lipid storage; IMP:MGI. DR GO; GO:0072676; P:lymphocyte migration; IMP:MGI. DR GO; GO:0007040; P:lysosome organization; IMP:UniProtKB. DR GO; GO:0014004; P:microglia differentiation; IMP:MGI. DR GO; GO:0061518; P:microglial cell proliferation; IMP:MGI. DR GO; GO:0007005; P:mitochondrion organization; IMP:MGI. DR GO; GO:0000423; P:mitophagy; IMP:MGI. DR GO; GO:0061744; P:motor behavior; IMP:MGI. DR GO; GO:0032715; P:negative regulation of interleukin-6 production; ISO:MGI. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IMP:MGI. DR GO; GO:0051248; P:negative regulation of protein metabolic process; IMP:ParkinsonsUK-UCL. DR GO; GO:0031333; P:negative regulation of protein-containing complex assembly; IMP:ParkinsonsUK-UCL. DR GO; GO:0050877; P:nervous system process; IMP:MGI. DR GO; GO:0050905; P:neuromuscular process; IMP:MGI. DR GO; GO:0051402; P:neuron apoptotic process; IMP:MGI. DR GO; GO:1904925; P:positive regulation of autophagy of mitochondrion in response to mitochondrial depolarization; IMP:ARUK-UCL. DR GO; GO:1904457; P:positive regulation of neuronal action potential; ISO:MGI. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IMP:ParkinsonsUK-UCL. DR GO; GO:0035307; P:positive regulation of protein dephosphorylation; ISO:MGI. DR GO; GO:1903061; P:positive regulation of protein lipidation; ISO:MGI. DR GO; GO:0043243; P:positive regulation of protein-containing complex disassembly; ISO:MGI. DR GO; GO:1903052; P:positive regulation of proteolysis involved in protein catabolic process; IMP:ARUK-UCL. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IMP:MGI. DR GO; GO:0021859; P:pyramidal neuron differentiation; IMP:MGI. DR GO; GO:0042391; P:regulation of membrane potential; IMP:MGI. DR GO; GO:0051246; P:regulation of protein metabolic process; IMP:ARUK-UCL. DR GO; GO:0032006; P:regulation of TOR signaling; IMP:UniProtKB. DR GO; GO:0022904; P:respiratory electron transport chain; IMP:MGI. DR GO; GO:0071548; P:response to dexamethasone; ISO:MGI. DR GO; GO:0043627; P:response to estrogen; ISO:MGI. DR GO; GO:0009268; P:response to pH; ISO:MGI. DR GO; GO:0033574; P:response to testosterone; ISO:MGI. DR GO; GO:0097066; P:response to thyroid hormone; ISO:MGI. DR GO; GO:0098773; P:skin epidermis development; ISO:MGI. DR GO; GO:0046512; P:sphingosine biosynthetic process; ISO:MGI. DR GO; GO:0033077; P:T cell differentiation in thymus; IMP:MGI. DR GO; GO:0023021; P:termination of signal transduction; ISO:MGI. DR Gene3D; 3.20.20.80; Glycosidases; 1. DR InterPro; IPR033452; GH30_C. DR InterPro; IPR001139; Glyco_hydro_30. DR InterPro; IPR033453; Glyco_hydro_30_TIM-barrel. DR InterPro; IPR017853; Glycoside_hydrolase_SF. DR PANTHER; PTHR11069; GLUCOSYLCERAMIDASE; 1. DR PANTHER; PTHR11069:SF23; LYSOSOMAL ACID GLUCOSYLCERAMIDASE; 1. DR Pfam; PF02055; Glyco_hydro_30; 1. DR Pfam; PF17189; Glyco_hydro_30C; 1. DR PRINTS; PR00843; GLHYDRLASE30. DR SUPFAM; SSF51445; (Trans)glycosidases; 1. DR SUPFAM; SSF51011; Glycosyl hydrolase domain; 2. DR Genevisible; P17439; MM. PE 1: Evidence at protein level; KW Cholesterol metabolism; Direct protein sequencing; Disulfide bond; KW Glycoprotein; Glycosidase; Glycosyltransferase; Hydrolase; KW Lipid metabolism; Lysosome; Membrane; Reference proteome; Signal; KW Sphingolipid metabolism; Steroid metabolism; Sterol metabolism; KW Transferase. FT SIGNAL 1..19 FT /evidence="ECO:0000250" FT CHAIN 20..515 FT /note="Lysosomal acid glucosylceramidase" FT /id="PRO_0000012178" FT ACT_SITE 254 FT /note="Proton donor" FT /evidence="ECO:0000250" FT ACT_SITE 358 FT /note="Nucleophile" FT /evidence="ECO:0000250" FT CARBOHYD 38 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 78 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 165 FT /note="N-linked (GlcNAc...) (high mannose) asparagine" FT /evidence="ECO:0000269|PubMed:16170054" FT CARBOHYD 289 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973" FT CARBOHYD 480 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 23..35 FT /evidence="ECO:0000250|UniProtKB:P04062" FT DISULFID 37..42 FT /evidence="ECO:0000250|UniProtKB:P04062" SQ SEQUENCE 515 AA; 57622 MW; 7CCD9176085FE2CB CRC64; MAARLIGFFL FQAVSWAYGA QPCIPKSFGY SSVVCVCNAS YCDSLDPVTL PALGTFSRYE STRRGRRMEL SVGAIQANRT GTGLLLTLQP EKKFQKVKGF GGAMTDATAL NILALSPPTQ KLLLRSYFST NGIEYNIIRV PMASCDFSIR VYTYADTPND FQLSNFSLPE EDTKLKIPLI HQALKMSSRP ISLFASPWTS PTWLKTNGRV NGKGSLKGQP GDIFHQTWAN YFVKFLDAYA KYGLRFWAVT AENEPTAGLF TGYPFQCLGF TPEHQRDFIS RDLGPALANS SHDVKLLMLD DQRLLLPRWA EVVLSDPEAA KYVHGIAVHW YMDFLAPAKA TLGETHRLFP NTMLFASEAC VGSKFWEQSV RLGSWDRGMQ YSHSIITNLL YHVTGWTDWN LALNPEGGPN WVRNFVDSPI IVDIPKDAFY KQPMFYHLGH FSKFIPEGSQ RVALVASEST DLETVALLRP DGSAVVVVLN RSSEDVPLTI SDPDLGFLET VSPGYSIHTY LWRRQ //